Clinical trials in Effingham, IL

22 recruiting studies have a site in or near Effingham, IL, Illinois.

Top conditions here

All conditions

Showing 22 of 22 studies

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Alton, IL · Aurora, IL · Barrington, IL · +1147 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Centralia, IL · Chicago, IL · +172 more sites

RecruitingPhase 3NCT07388524

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Sponsor: National Cancer Institute (NCI)

Bloomington, IL · Canton, IL · Carthage, IL · +97 more sites

RecruitingPhase 3NCT07391774

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Sponsor: National Cancer Institute (NCI)

Bloomington, IL · Canton, IL · Carterville, IL · +200 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Chicago, IL · +222 more sites

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Bloomington, IL · Canton, IL · Carthage, IL · +275 more sites

RecruitingPhase 3NCT03678025

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Sponsor: SWOG Cancer Research Network

Aurora, IL · Bloomington, IL · Canton, IL · +331 more sites

RecruitingPhase not listedNCT03998202

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Sponsor: Wake Forest University Health Sciences

Bloomington, IL · Canton, IL · Carterville, IL · +144 more sites

RecruitingPhase not listedNCT05334069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Sponsor: Alliance for Clinical Trials in Oncology

Alton, IL · Aurora, IL · +744 more sites

RecruitingPhase 2NCT06632977

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Sponsor: Alliance for Clinical Trials in Oncology

Bloomington, IL · Canton, IL · Danville, IL · +105 more sites

RecruitingNot applicableNCT07283939

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Sponsor: Alliance for Clinical Trials in Oncology

Alton, IL · Bloomington, IL · Canton, IL · +357 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Alton, IL · Aurora, IL · +1223 more sites

RecruitingPhase 3NCT04423211

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Sponsor: ECOG-ACRIN Cancer Research Group

Alton, IL · Aurora, IL · +338 more sites

RecruitingPhase 3NCT05812807

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Sponsor: Alliance for Clinical Trials in Oncology

Aurora, IL · Barrington, IL · +825 more sites

RecruitingPhase 3NCT06748222

E-Mindfulness Approaches for Living After Breast Cancer

Sponsor: NRG Oncology

Arlington Heights, IL · Aurora, IL · Bloomington, IL · +378 more sites

RecruitingPhase 3NCT06686771

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Sponsor: Canadian Cancer Trials Group

Alton, IL · Chicago, IL · Decatur, IL · +68 more sites

RecruitingPhase 2NCT05642572

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Barrington, IL · Bloomington, IL · Canton, IL · +451 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Alton, IL · Aurora, IL · +1226 more sites

RecruitingPhase 3NCT04852887

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sponsor: NRG Oncology

Alton, IL · Aurora, IL · +809 more sites

RecruitingPhase 3NCT06470243

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Sponsor: SWOG Cancer Research Network

Bloomington, IL · Canton, IL · Carbondale, IL · +171 more sites

RecruitingPhase not listedNCT06073431

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

Sponsor: University of Rochester

Alton, IL · Barrington, IL · Bloomington, IL · +222 more sites

RecruitingPhase 3NCT05929768

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Sponsor: SWOG Cancer Research Network

Alton, IL · Aurora, IL · +952 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.